Subscription: Free

  • BUY : NIFTY26JUN25FUT( NIFTY ) [56785]

    by

    Rationale: I have witnessed breakout on short term technical chart. We have also witnessed up trend, positive range breakout and positive long buildup in future and with price gain and RSI strength on 50. please find stock chart below for the reference: –

  • BUY : ADANIGREEN31JUL25FUT( ADANIGREEN ) [53225]

    by

    Rationale: I have witnessed breakout on short term technical chart. We have also witnessed up trend, positive range breakout and positive future long and option data short covering in call and RSI strength on 50.  please find stock chart below for the reference: –

  • BUY : INDHOTEL31JUL25FUT( INDHOTEL ) [53338]

    by

    Rationale: I have witnessed breakout on short term technical chart. We have also witnessed up trend, positive range breakout and positive future long and option data short covering in call and RSI strength on 50.  please find stock chart below for the reference: –  

  • BUY : HINDCOPPER-EQ( HINDCOPPER ) [17939]

    by

    Price has broken out of the previous swing high supporting buy good volume.

  • BUY : BEML-EQ( BEML ) [395]

    by

    BEML Limited shows strong bullish momentum backed by stellar Q4 results, with revenue surging 1062% QoQ, reflecting robust order execution in defense, rail, and mining sectors. The government’s focus on infrastructure, defense modernization, and metro expansion further strengthens growth prospects. Technically, the stock has broken key resistance levels and is trading above major moving averages,…

  • BUY : ITC-EQ( ITC ) [1660]

    by

    ITC Limited presents a strong buy opportunity at ₹436, supported by its diversified business model, consistent earnings, and leadership in the FMCG segment. The stock has shown bullish momentum with improving volume and is trading near key support levels, making risk-reward highly favorable. Recent market optimism and investor confidence in defensive stocks like ITC further…

  • BUY : ZYDUSLIFE-EQ( ZYDUSLIFE ) [7929]

    by

    Zydus Lifesciences Limited is showing strong bullish momentum backed by consistent earnings growth, a robust product pipeline, and regulatory approvals in key global markets. Technically, the stock has broken out of a consolidation phase and is trading above key moving averages, indicating strength. Buying at ₹903 offers a favorable risk-reward setup with an upside target…